SCHEDULE 13G/A: BlackRock Amends Passive Stake in Lineage Cell Therapeutics, Reports 4.6% Beneficial Ownership
Schedule 13G Filing
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in Lineage Cell Therapeutics Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 10,094,677 shares of Lineage Cell Therapeutics Inc. common stock.
- This represents 4.6% of the total outstanding common stock of Lineage Cell Therapeutics Inc. for the specified reporting business units of BlackRock, Inc.
- BlackRock holds sole voting power over 10,051,108 shares and sole dispositive power over 10,094,677 shares.
- No shared voting or dispositive power was reported by BlackRock, Inc. for these reporting units.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer.
- One of BlackRock's subsidiaries, BlackRock Investment Management, LLC, is specifically noted as beneficially owning 5% or greater of the outstanding shares of Lineage Cell Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing passive ownership, which is neutral in sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake in Lineage Cell Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-01-21 | Date of execution of the Power of Attorney for filing purposes. |
| 2025-02-05 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Lineage Cell Therapeutics, SEC filing, Schedule 13G, beneficial ownership, institutional investor, common stock, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.